CRC Research Update — August 03, 2026
Today's colorectal cancer research highlights
side-effects
A collection of 45 issues
CRC Research Update — August 02, 2026
Today's colorectal cancer research highlights
Lean Body Mass Linked to Oxaliplatin Neuropathy Risk
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Lean Body Mass Linked to Oxaliplatin Neuropathy Risk
A study of colorectal cancer patients receiving adjuvant CAPOX found that lean body mass and sarcopenia may influence the risk of dose-limiting peripheral neuropathy, suggesting current body-surface-area dosing may not account for important
CRC Research Update — August 01, 2026
Today's colorectal cancer research highlights
Traditional Chinese Medicine formula shows benefit for chemotherapy side effects in real-world study
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Traditional Chinese Medicine formula shows benefit for chemotherapy side effects in real-world study
In a propensity-matched analysis of 178 colorectal cancer patients, those receiving a standardized TCM formula alongside fluoropyrimidine chemotherapy had reduced gastrointestinal toxicity and improved quality of life compared
Systematic review evaluates treatments for bowel dysfunction after colorectal cancer surgery
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Systematic review evaluates treatments for bowel dysfunction after colorectal cancer surgery
Eight studies examined pharmacological therapies including serotonin receptor antagonists, herbal medicines, diazepam, and Botulinum A toxin for managing bowel dysfunction following sphincter-preserving surgeries. (Adv Pharm Bull)
This content is informational
CRC Research Update — July 30, 2026
Today's colorectal cancer research highlights
CRC Research Update — July 27, 2026
Today's colorectal cancer research highlights
Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy
A multicenter study of 452 colorectal cancer patients who received neoadjuvant immunotherapy analyzed the incidence of immune-related adverse events and perioperative outcomes following curative surgery. (Zhonghua Wei Chang Wai Ke Za Zhi)
Validated Scale Helps Measure Treatment-Induced Neuropathy in Chinese Patients
Skip to content
The CRC Digest
Validated Scale Helps Measure Treatment-Induced Neuropathy in Chinese Patients
A prospective study of 254 colorectal cancer patients receiving oxaliplatin validated the Treatment-induced Neuropathy Assessment Scale (TNAS) and established cutpoints for numbness, sensory symptoms, and interference with daily activities. (Quality of Life Research)
This content